Hematologic Malignancies: Myeloproliferative Disorders - part 4 pot
Hematologic Malignancies: Myeloproliferative Disorders - part 4 pot
... 23 2 881 28 47 62 31 32 3 867 28 37 48 46 31 4 485 15 35 40 51 28 5 2 147 19187 141 6 57 2 16 22 73 32 7 4 –––– 5-year probability of leukemia-free survival (LFS), survival, transplant-related mortality ... yrs CP 43 % at 3yrs 54% at 3 yrs CP1 60% at 3yrs (Ruiz-Arguelles et al. 2005) 24 Bu/Cy/Fd 24 CP 24 Sib 41 yrs 18/ 24 molecular remissions 5/ 24 Cytoge- netic 15 months 8%...
Ngày tải lên: 10/08/2014, 16:22
Hematologic Malignancies: Myeloproliferative Disorders - part 9 potx
... patients D Gary Gilliland 74% 33% 35% (Cancer Cell 7:387, 2005) 121 of 1 64 patients 37 of 115 patients 16 of 46 patients William Vainchenker 89% 43 % 43 % (Nature 43 4:1 144 , 2005) 40 of 45 patients 9 of 21 ... hypoxia-induci- ble factor 1 in transcriptional response of hypoxia. Proc Nat Acad Sci U SA 90 :43 04 43 08 Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible fac-...
Ngày tải lên: 10/08/2014, 16:22
Hematologic Malignancies: Myeloproliferative Disorders - part 10 potx
... fusions 2 24 fibrocystic pulmonary dysplasia 298 fibronectin 256 fibrosis 242 FIP1L1-PDGFRA 222, 235, 236, 240 , 241 , 245 FK506 94 FKBP-12 94 flavopiridol 5 FLT 226 FLT3 226 fludarabine 1 24, 268 fluorescence ... 158 glycoprotein 1 04 GM-CSF 196 graft-versus-host disease (GvHD) 9, 120, 126, 187, 189, 197 graft-versus-leukemia (GvL) effect 121, 127, 171, 212 graft-versus-myelofibrosis...
Ngày tải lên: 10/08/2014, 16:22
Hematologic Malignancies: Myeloproliferative Disorders - part 1 ppsx
... USA London W12 0NN UK ISBN-10 3-5 4 0-3 45 0 5-1 Springer Berlin Heidelberg New York ISBN-13 97 8-3 - 54 0-3 45 0 5-3 Springer Berlin Heidelberg New York Library of Congress Control Number: 200692 642 8 A catalog record ... p52 by the Bcr-Abl phos- pho-Tyr residue located at position 12 94 of the TK do- main, which, after the formation of a Shc-Grb2 complex, has the potent...
Ngày tải lên: 10/08/2014, 16:22
Hematologic Malignancies: Myeloproliferative Disorders - part 2 doc
... (with permission from Hehl- mann et al. 19 94) IFN (n =133) Bu (n =186) HU (n = 1 94) Age years median(range) 47 .4 14. 9 /47 (18–85) 48 .5±15.5 /4. 9(17– 84) 46 .9±15.3 /47 (15– 84) Sex (% male) 66.2 61.3 ... downregulated in Bcr-Abl-induced mur- ine chronic myelogenous leukemia-like disease, and forced coex- pression of ICSBP inhibits Bcr-Abl-induced myeloproliferative dis- order. M...
Ngày tải lên: 10/08/2014, 16:22
Hematologic Malignancies: Myeloproliferative Disorders - part 6 pdf
... from geneti- cally-identical twins, allotransplant recipients without graft-versus-host-disease (GvHD), and recipients of T- cell-depleted allotransplants all have increased leuke- mia-relapse ... Proteasome inhibition may block NF-jB through decreased inacti- vation of IjB (Adams et al. 1999). In CML, Bcr-Abl ac- tivates NF-jB-dependent transcription and NF-jBmay be required for BCR-ABL-medi...
Ngày tải lên: 10/08/2014, 16:22
Hematologic Malignancies: Myeloproliferative Disorders - part 7 ppsx
... J, Borzilleri RM (20 04) Discovery of N-(2-chloro-6-methyl- phenyl )- 2-( 6-( 4- ( 2-hydroxyethyl)-piperazin-1-yl )-2 -methylpyrimidin -4 yla- mino)thiazole-5-carboxamide (BMS-3 548 25), a dual Src/Abl ... immature T-cells (CD3+CD4–CD8– or CD3–CD4+CD8–) (Brugnoni et al. 1997; Cogan et al. 19 94) , and elevated levels of IgE, IL-5, and in some cases IL -4 and IL-13, suggesting that...
Ngày tải lên: 10/08/2014, 16:22
Hematologic Malignancies: Myeloproliferative Disorders - part 8 ppsx
... contain in- creased levels of cytoplasmic TGF-b and IL-1 (Ramesh- war et al. 19 94) . It has also been hypothesized that extra- cellular matrix protein-adhesion molecule interactions, involving CD 44, ... cytokines. Potential role for interleukin-1 and TGF-b. J Immunol 153:2819–2830 Rameshwar P, Chang VT, Gascon P (1996) Implication of CD 44 in ad- hesion-mediated overproduction of TGF-b and...
Ngày tải lên: 10/08/2014, 16:22
Chapter 076. Eating Disorders (Part 4) pot
... medical problems, such as severe electrolyte imbalances, should be Chapter 076. Eating Disorders (Part 4) Table 7 6-2 Diagnostic Features of Anorexia Nervosa Refusal to maintain body weight at ... central nervous system (CNS) tumors, or neoplasm (Chap. 41 ). Prognosis The course and outcome of AN are highly variable. One-quarter to one-half of patients eventually recover ful...
Ngày tải lên: 07/07/2014, 01:20
Chapter 110. Coagulation Disorders (Part 4) potx
... The FVIII half-life of 8–12 h requires injections twice a day to maintain therapeutic levels, whereas the FIX half-life is longer, ~ 24 h, so that once-a-day injection is sufficient. ... replacement for 1–3 days coupled with oral antifibrinolytic drugs. Non-Transfusion Therapy in Hemophilia DDAVP (1-Deamino-8-D-Arginine Vasopressin) DDAVP is a synthetic vasopressin analogue that ......
Ngày tải lên: 07/07/2014, 04:20